Safety and Immunogenicity of a Single Dose of Menactra Vaccine 4-6 Years After Prior Menactra Vaccine

Trial Profile

Safety and Immunogenicity of a Single Dose of Menactra Vaccine 4-6 Years After Prior Menactra Vaccine

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 15 Sep 2016 Results assessing safety and immunogenicity of booster dose published in the Vaccine (2016).
    • 08 Sep 2014 Results published in the Media Release.
    • 08 Sep 2014 Menactra was approved in the US for booster vaccination of subjects aged 15-55 years, based on results from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top